chloroquine has been researched along with Proteinuria in 13 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 11 (84.62) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (15.38) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abud-Mendoza, C | 1 |
de la Fuente, H | 1 |
Cuevas-Orta, E | 1 |
Baranda, L | 1 |
Cruz-Rizo, J | 1 |
González-Amaro, R | 1 |
SHINOHARA, M | 1 |
KOSAKA, M | 1 |
SUZUKI, T | 1 |
TSUNOKAKE, H | 1 |
TSUJI, S | 1 |
SHEARN, MA | 1 |
OTANI, H | 1 |
YAMAMOTO, H | 1 |
HIRASAWA, S | 1 |
BETSUYAKU, I | 1 |
ITO, N | 1 |
YACHI, A | 1 |
Scotti da Silva-Colombeli, A | 1 |
Falkenberg, M | 1 |
Poels, LG | 1 |
van Niekerk, CC | 1 |
Pennings, L | 1 |
Agterberg, J | 1 |
van Elven, EH | 1 |
Zweiman, B | 1 |
Kornblum, J | 1 |
Cornog, J | 1 |
Hildreth, EA | 1 |
Campbell, CH | 1 |
Holiday, J | 1 |
Biggs, JC | 1 |
Backhouse, TC | 1 |
Missmahl, HP | 2 |
Brass, H | 1 |
Lapp, H | 1 |
Heintz, R | 1 |
Tarejew, EM | 1 |
Poljanzewa, LR | 1 |
Muchin, NA | 1 |
Mosgowa, LA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis[NCT00302952] | Phase 2 | 64 participants (Actual) | Interventional | 2007-11-06 | Terminated (stopped due to Slow enrollment &Study Drug Expiration (Target: 40 randomized participants /arm)) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Blood draw for CRP, an acute phase reactant used to identify the presence of nonspecific inflammation. Change=Day 84 value minus Baseline value. Normal serum CRP reference range in this study is 0-4 mg/L (log transformed: -4.2 to 1.4). Participants with measurements for designated time points were included in analysis. An increased CRP level indicates the presence of inflammation. Reduced CRP levels could mean a decrease in inflammation. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | mg/L (Mean) |
---|---|
Lovastatin 80 mg | -0.4 |
Placebo | -0.3 |
Anti-CCP antibodies are autoantibodies frequently detected in the serum of individuals with rheumatoid arthritis. In this study, a positive value for anti-CCP was 8 IU/mL or greater; a negative value for anti-CCP was <8 IU/mL. Change= subtraction of Day 0 from Day 84 anti-CCP value. In general, high levels of the antibody indicate an aggressive rheumatoid arthritis and a higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline ( Day 0), Day 84 (Wk 12)
Intervention | IU/mL (Mean) |
---|---|
Lovastatin 80 mg | 16.3 |
Placebo | -1.0 |
Rheumatoid factor (RF) is an antibody often present in the blood of a person with rheumatoid arthritis. In this study, a positive value for RF was 0.5 IU/mL or greater; a negative value for RF was <0.5 IU/mL. Change= Day 84 value minus Baseline value. In general, presence of the antibody indicates aggressive rheumatoid arthritis and higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | IU/mL (Mean) |
---|---|
Lovastatin 80 mg | -5.4 |
Placebo | 2.8 |
The DAS28-CRP score is on a scale of 0 to 10 and indicates current activity of rheumatoid arthritis (>5.1=high disease activity; 3.2-<=5.1=moderate disease activity; <=3.2=low disease activity; <2.6=remission). The score uses a combination of four variables: 1) the number of tender joints (of the 28 that are measured); 2) the number of swollen joints (of the 28 that are measured); 3) serum C-reactive protein (CRP) lab value in mg/L , and 4) Patient Global Assessment of Disease Activity. Using a formula, the physician determines the score. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0) to Day 84 (Wk 12)
Intervention | Scores on a scale (Mean) |
---|---|
Lovastatin 80 mg | -0.5 |
Placebo | -0.5 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | U/L (Mean) |
---|---|
Lovastatin 80 mg | -2.4 |
Placebo | 8.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | % of packed red blood cells by volume (Mean) |
---|---|
Lovastatin 80 mg | -0.5 |
Placebo | -0.5 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | pg (Mean) |
---|---|
Lovastatin 80 mg | -0.4 |
Placebo | 0.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | fL (Mean) |
---|---|
Lovastatin 80 mg | -0.4 |
Placebo | 0.7 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | % of mean corpuscle volume (Mean) |
---|---|
Lovastatin 80 mg | -0.4 |
Placebo | 0.2 |
Patients were ACR20 Responders if they had: at least 20% improvement in both tender joint count (28 examined) and swollen joint count (28 examined), and 20% improvement in at least three of the following 5 remaining ACR core measures: • Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm) • Patient's global assessment of disease activity (VAS 100 mm) • Physician's global assessment of disease activity (VAS 100 mm) • Patient self-assessed disability (Health Assessment Questionnaire (HAQ)) score • Acute phase reactant C-reactive protein. Participants with measurements for designated time points were included in analysis. (NCT00302952)
Timeframe: Day 84 (Wk 12)
Intervention | Percentage of participants (Number) |
---|---|
Lovastatin 80 mg | 29.0 |
Placebo | 40.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | g/dL (Mean) | |||
---|---|---|---|---|
Albumin | Total Protein | Hemoglobin | MCHC | |
Lovastatin 80 mg | 0.0 | 0.0 | -0.3 | -0.3 |
Placebo | 0.1 | 0.1 | -0.3 | -0.4 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | U/L (Mean) | ||
---|---|---|---|
Alkaline Phosphatase | ALT | AST | |
Lovastatin 80 mg | -3.0 | -1.8 | -1.2 |
Placebo | 0.4 | 0.7 | 0.8 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | 10^3/uL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
WBC | Neutrophils | Bands | Lymphocytes | Monocytes | Eosinophils | Basophils | Platelet Count | Reticulocytes | |
Lovastatin 80 mg | 0.1 | 0.2 | 0.0 | -0.1 | 0.1 | 0.0 | 0.0 | -8.2 | -4.7 |
Placebo | -0.4 | -0.6 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | -5.6 | 0.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | mmol/L (Mean) | |||
---|---|---|---|---|
Potassium | Sodium | Chloride | Total CO2 | |
Lovastatin 80 mg | 0.0 | -0.2 | -0.1 | 0.7 |
Placebo | 0.0 | -0.2 | 0.5 | -0.5 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | mg/dL (Mean) | |||||
---|---|---|---|---|---|---|
Total Bilirubin | Creatinine | BUN | Phosphorus | Calcium | Glucose | |
Lovastatin 80 mg | 0.0 | 0.0 | -0.4 | 0.0 | 0.0 | -4.3 |
Placebo | 0.1 | 0.0 | -0.5 | 0.0 | 0.0 | -1.2 |
1 review available for chloroquine and Proteinuria
Article | Year |
---|---|
[Amyloidosis in chronic rheumatic diseases].
Topics: Adult; Aged; Amyloidosis; Arthritis, Rheumatoid; Biopsy; Chloroquine; Chronic Disease; Collagen Dise | 1968 |
1 trial available for chloroquine and Proteinuria
Article | Year |
---|---|
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; | 2003 |
11 other studies available for chloroquine and Proteinuria
Article | Year |
---|---|
[Pregnancy toxemias, with special reference to the effect of chloroquine diorotate (Kidola) on proteinuria].
Topics: Chloroquine; Female; Pre-Eclampsia; Pregnancy; Proteinuria; Toxemia | 1963 |
[ON PROTEINURIA].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Chloroquine; Diagnosis, Differential; Humans; | 1963 |
NORMOCHOLESTEROLEMIC NEPHROTIC SYNDROME OF SYSTEMIC LUPUS ERYTHEMATOSUS.
Topics: Adolescent; Body Weight; Chloroquine; Cholesterol; Humans; Hypercholesterolemia; Lupus Erythematosus | 1964 |
[Pathophysiological studies on serum and urinary protein pattern with reference to the influence of chloroquine-diorotate (Kidola) on nephropathy].
Topics: Chloroquine; Humans; Kidney Diseases; Mucoproteins; Orotic Acid; Proteinuria; Serum Albumin | 1962 |
Analytical interferences of drugs in the chemical examination of urinary protein.
Topics: Chloroquine; Ciprofloxacin; Clinical Laboratory Techniques; Humans; Pharmaceutical Preparations; Pro | 2007 |
Plasmodium berghei: formation of secondary immune complexes in hyperimmune mice.
Topics: Animals; Antigen-Antibody Complex; Antigens; Chloroquine; Complement System Proteins; Immunoglobulin | 1977 |
The prognosis of lupus nephritis. Role of clinical-pathologic correlations.
Topics: Adrenocorticotropic Hormone; Blood Urea Nitrogen; Chloroquine; Follow-Up Studies; Histological Techn | 1968 |
Chloroquine-resistant Falciparum malaria acquired in Vietnam.
Topics: Acute Kidney Injury; Adolescent; Adult; Blood Cell Count; Chloroquine; Dapsone; Drug Resistance, Mic | 1973 |
[Long term treatment of chronic glomerulonephritis, clinical course and results of renal biopsies].
Topics: Acetates; Adolescent; Adult; Azathioprine; Biopsy; Blood Pressure; Chloroquine; Female; Glomerulonep | 1969 |
[Amyloidosis in ankylosing spondylitis].
Topics: Amyloidosis; Biopsy; Chloroquine; Diagnosis, Differential; Female; Humans; Kidney Failure, Chronic; | 1969 |
[Trial of resochin therapy in diffuse kidney diseases].
Topics: Amyloidosis; Animals; Chloroquine; Chronic Disease; Collagen Diseases; Glomerulonephritis; Humans; K | 1966 |